Skip to main content
HR 5385 118th Congress House Health Accounting and auditing Congressional oversight Contracts and agency Drug safety, medical device, and laboratory regulation Government information and archives Government studies and investigations Health care costs and insurance Prescription drugs Retail and wholesale trades

Medicare PBM Accountability Act

Introduced: September 12, 2023 Introduced by: Landsman, Greg Democratic · Ohio See on congress.gov
 Everywhere this bill has been 9 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Dec 17, 2024
Referred to the Subcommittee on Health.
Dec 6, 2023
Ordered to be Reported (Amended) by the Yeas and Nays: 44 - 0.
Dec 6, 2023
Committee Consideration and Mark-up Session Held
Dec 5, 2023
Committee Consideration and Mark-up Session Held
Nov 15, 2023
Forwarded by Subcommittee to Full Committee by Voice Vote.
Nov 15, 2023
Subcommittee Consideration and Mark-up Session Held
Sep 15, 2023
Referred to the Subcommittee on Health.
Sep 12, 2023
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sep 12, 2023
Introduced in House
 Plain-English summary Congressional Research Service

Medicare PBM Accountability Act

This bill establishes reporting requirements for pharmacy benefit managers (PBMs) under the Medicare prescription drug benefit and Medicare Advantage, particularly relating to the prices of prescription drugs.

Specifically, PBMs must (1) disclose certain information underlying cost performance measurements (e.g., exclusions and terms), and (2) report to prescription drug plan (PDP) sponsors (and to the Centers for Medicare & Medicaid Services upon request) an itemized list of prescription drugs that were dispensed during the previous year and related data about costs, claims, affiliated pharmacies, and other specified information. PDP sponsors may audit PBMs to ensure compliance with this bill's requirements and must annually certify their compliance; PBMs are responsible for any associated civil penalties for violations.

In addition, the Government Accountability Office must study federal and state reporting requirements for health plans and PBMs with respect to prescription drug price transparency and recommend ways to streamline these requirements.

What's happening now December 17, 2024

Referred to the Subcommittee on Health.

 Committees of jurisdiction 4